Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Aartselaar – page 104

2 143 clinical trials in Aartselaar, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Aartselaar at a glance
2 143
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 143 trials in Aartselaar

Open in trial search

Influenza

Not recruiting

Study on the Effectiveness and Safety of CR9114 for Preventing Influenza in Healthy Adults

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:CR9114
  • Sponsor:Leyden Laboratories B.V.

Pertussis

Not recruiting

Study on How Vaccines Affect Infant Immunity to Whooping Cough in Babies Born to Vaccinated Mothers Using Diphtheria, Tetanus, and Pertussis Vaccine Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Diphtheria toxoid
  • Sponsor:Universite Libre de Bruxelles

Lipoedema

Not recruiting

Study on the Use of Indocyanine Green to Assess Lymphatic Vessel Porosity in Women with Lipedema

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Indocyanine Green
  • Sponsor:Universite Libre de Bruxelles

Escherichia infection

Not recruiting

Study on Ciprofloxacin's Effect on Antibiotic Resistance in E. coli for Healthy Individuals

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ciprofloxacin
  • Sponsor:Institute Of Tropical Medicine

Influenza

Not recruiting

A Study of OVX836 Influenza Vaccine Given as Booster or Primary Vaccination in Healthy Adults Who Previously Received OVX836, Influenza Vaccine, or Placebo

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:INFLUENZA A (H1N1/WSN/1933) NUCLEOPROTEIN FUSED TO C-TERMINAL FRAGMENTS OF TWO AVIAN C4BP ALFA CHAIN SEQUENCES
  • Sponsor:OSIVAX Belgique

Title: Study of LP352 (bexicaserin) oral solution versus placebo for treating seizures in children and adults with Developmental and Epileptic Encephalopathies

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bexicaserin hydrochloride
  • Sponsor:Longboard Pharmaceuticals Inc.

COVID-19

Not recruiting

Study on the Immune Response to Bretovameran COVID-19 mRNA Vaccine in Healthy Adults Aged 18-40

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Bretovameran
  • Sponsor:University Of Antwerp

Study on the Effects and Safety of GLM101 for Patients with PMM2-CDG

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Glycomine Inc.

Herpes simplex

Not recruiting

Study of HSV immunotherapy (HSVTI) for healthy adults aged 18-40 and people with recurrent genital herpes aged 18-60

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:GSKVX000000030810
  • Sponsor:GlaxoSmithKline Biologicals
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Rifaximin
  • Sponsor:UZ Leuven

Drug use disorder

Not recruiting

Study on the Effects of Naloxegol and Codeine on Opioid-Induced Constipation in Healthy Volunteers

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Bisacodyl
  • Sponsor:UZ Leuven
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Lactose Monohydrate
  • Sponsor:Universiteit Gent

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Aartselaar

What the registry says about research in the country

01 Infectious Disease Research

Pioneering research examining SARS-CoV-2 immunity patterns in immunocompromised populations, focusing on long-term antibody responses to viral variants.

  • Immunity Monitoring
  • Vulnerable Populations
  • Antibody Response Assessment

This study specifically includes nursing home residents, dialysis patients, and transplant recipients aged 18-105.

02 Viral Infection Treatment

Clinical evaluation of novel therapeutic approaches for managing Epstein-Barr Virus infections, with a focus on reducing fatigue symptoms.

  • Fatigue Management
  • Treatment Efficacy
  • Symptom Control

The research employs a rigorous double-blind methodology to assess treatment effectiveness against asthenia.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.